Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bardin

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 7, 2013
The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healingJ Jeyabalan, B Viollet, P Smitham, et al.
Pharmacy World & Science : PWS|February 5, 2000
Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitalsI Debrix, I Madelaine, N Grenet, et al.
Diabetes & Metabolism|June 30, 2001
Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local toleranceD Lalej-Bennis, J Boillot, C Bardin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 13, 2001
Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over studyD Lalej-Bennis, J Boillot, C Bardin, et al.
Anti-Cancer Drugs|May 2, 2000
Multicenter study of the impact of prescription guidelines on the use of colony stimulating factorsN Grené, A Pointereau-Bellanger, O Conort, et al.
Diabetes & Metabolism|March 13, 1998
Extreme insulin resistance: clinical management by external subcutaneous insulin infusionD Lalej-Bennis, J L Selam, S Fluteau-Nadler, et al.
Canadian Family Physician Medecin De Famille Canadien|February 1, 1997
Attitudes toward obstetrics training. Residents surveyed at McGill University and University of MontrealC Levitt, N Khanlou, J Kaczorowski, et al.
British Journal of Cancer|July 19, 2006
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaV Lévy, S Zohar, C Bardin, et al.
Brain : a Journal of Neurology|March 1, 2011
Dissociations between behavioural and functional magnetic resonance imaging-based evaluations of cognitive function after brain injuryJonathan C Bardin, Joseph J Fins, Douglas I Katz, et al.
Clinical Therapeutics|August 25, 2001
The relationship between introduction of American society of clinical oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospitalI Debrix, P Tilleul, B Milleron, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 7, 2013
The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healingJ Jeyabalan, B Viollet, P Smitham, et al.
Pharmacy World & Science : PWS|February 5, 2000
Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitalsI Debrix, I Madelaine, N Grenet, et al.
Diabetes & Metabolism|June 30, 2001
Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local toleranceD Lalej-Bennis, J Boillot, C Bardin, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 13, 2001
Efficacy and tolerance of intranasal insulin administered during 4 months in severely hyperglycaemic Type 2 diabetic patients with oral drug failure: a cross-over studyD Lalej-Bennis, J Boillot, C Bardin, et al.
Anti-Cancer Drugs|May 2, 2000
Multicenter study of the impact of prescription guidelines on the use of colony stimulating factorsN Grené, A Pointereau-Bellanger, O Conort, et al.
Diabetes & Metabolism|March 13, 1998
Extreme insulin resistance: clinical management by external subcutaneous insulin infusionD Lalej-Bennis, J L Selam, S Fluteau-Nadler, et al.
Canadian Family Physician Medecin De Famille Canadien|February 1, 1997
Attitudes toward obstetrics training. Residents surveyed at McGill University and University of MontrealC Levitt, N Khanlou, J Kaczorowski, et al.
British Journal of Cancer|July 19, 2006
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaV Lévy, S Zohar, C Bardin, et al.
Brain : a Journal of Neurology|March 1, 2011
Dissociations between behavioural and functional magnetic resonance imaging-based evaluations of cognitive function after brain injuryJonathan C Bardin, Joseph J Fins, Douglas I Katz, et al.
Clinical Therapeutics|August 25, 2001
The relationship between introduction of American society of clinical oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospitalI Debrix, P Tilleul, B Milleron, et al.
Pageof 7